Back to top

Silence announces results from Phase 2 SANRECO trial met primary endpoint

Silence Therapeutics (SLN) announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Silence Therapeutics PLC Sponsored ADR (SLN)